---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018170"
form_type: "8-K"
ticker: "ANIX"
cik: "0000715446"
company_name: "Anixa Biosciences Inc"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T14:34:16.724002+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Anixa expands Cleveland Clinic joint development to develop additional cancer vaccines

## Summary
- Anixa and Cleveland Clinic entered Joint Development and Option Agreement to develop vaccines for multiple cancers.
- Anixa to pay non-refundable option fee and development funding in three tranches; first due May 8, 2024.
- Option to obtain exclusive, royalty-bearing worldwide license to inventions developed under agreement.
- Builds on existing breast cancer (Phase 1 TNBC) and ovarian cancer vaccine programs with Cleveland Clinic.
- Research led by Dr. Thaddeus Stappenbeck and Dr. Justin Johnson at Cleveland Clinic.

## SEC filing metadata
- accession: 0001493152-24-018170
- form_type: 8-K
- ticker: ANIX
- cik: 0000715446
- company_name: Anixa Biosciences Inc
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/715446/000149315224018170/0001493152-24-018170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/715446/000149315224018170/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018170
- JSON: https://secwatch.observer/filing/0001493152-24-018170.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018170.txt

## Key facts
- Material Agreements
  Anixa Biosciences Inc entered into Joint Development and Option Agreement with Cleveland Clinic Foundation valued at Company will pay CCF a non-refundable, option fee on or before May 23, 2024, and development funding (effective 2024-05-03).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Cleveland Clinic Foundation
  - Value: Company will pay CCF a non-refundable, option fee on or before May 23, 2024, and development funding
  - Effective: 2024-05-03
  source text: On May 3, 2024, Anixa Biosciences, Inc. (the “ Company ”) and the Cleveland Clinic Foundation (the “ CCF ”) entered into a Joint Development and Option Agreement (the “ Agreement ”). Pursuant to the Agreement, the parties agreed on the terms and conditions under which the parties will collaborate in efforts to develop vaccines for the prevention or treatment of cancers in the Fields.
  evidence_url: https://www.sec.gov/Archives/edgar/data/715446/000149315224018170/0001493152-24-018170-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.